Potent Nav1.7 blocker (IC50 = 2.5 nM). Also inhibits Nav1.1, Nav1.2, Nav1.3 and Nav1.6 in the nanomolar range. Exhibits no effects on Cav channels or nAChR at 5 μM. Demonstrates analgesic activity in vivo; antagonizes effects of scorpion-venom toxin OD1 at Nav1.7.
(Modifications: Disulfide bridge: 2-17, 9-22, 16-29, Ile-33 = C-terminal amide)
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 1 mg/ml in water|
References are publications that support the biological activity of the product.
Cardoso et al (2015) Identification and characterization of ProTx-III [μ-TRTX-Tp1a], a new voltage-gated sodium channel inhibitor from venom of the tarantula thrixopelma pruriens. Mol.Pharmacol. 88 291 PMID: 25979003
If you know of a relevant reference for ProTx III, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: ProTx III, ProTx III supplier, Potent, Nav1.7, blockers, inhibitors, inhibits, Nav1.1,, Nav1.2,, Nav1.3, Nav1.6, analgesics, voltage, gated, sodium, channels, venoms, Voltage-gated, Sodium, Channels, 5792, Tocris Bioscience
Citations for ProTx III
Citations are publications that use Tocris products.
Currently there are no citations for ProTx III. Do you know of a great paper that uses ProTx III from Tocris? Please let us know.
Reviews for ProTx III
There are currently no reviews for this product. Be the first to review ProTx III and earn rewards!
Have you used ProTx III?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.